Salonee Shah1, Kerri Beckmann1,2, Oussama Elhage3, Aida Santaolalla4, Mieke Van Hemelrijck1, Ben Challacombe3, Rick Popert3, Prokar Dasgupta3, Jonah Rusere3, Grace Zisengwe3. 1. King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK. 2. Cancer Research Institute, University of South Australia, Adelaide, Australia. 3. King's College London & Guy's and St Thomas' NHS Foundation Trust, London, UK. 4. King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology & Urology Research (TOUR), London, UK. aida.santaolalla@kcl.ac.uk.
Correction to: BMC Cancer 21, 573 (2021)https://doi.org/10.1186/s12885-021-08255-zFollowing publication of the original article [1], the authors reported an omission from the funding statement. The correct funding statement is supplied below:This work was supported by the department of Translational Oncology and Urology Research (TOUR) at King’s College London, Medical Research Council Grant no: MR/R014043/1. The views expressed are those of the author(s) and the funding body had no role in the design of the study and collection, analysis, and interpretation of data in writing the manuscript. Kerri Beckmann is supported by national health and medical research council (NHMRC) ECR fellowship GNT 1124210.